Early results of a "First‐in‐Human" Phase 1 clinical study of intracerebroventricular injections of ex vivo expanded, autologous, Wnt‐activated, adipose‐derived stem cells in participants with mild to moderate Alzheimer's Disease (AD)
This "first-in-human" trial of intracerebroventricular injection of expanded autologous, Wnt-expressing, adipose tissue-derived stem cells proved well-tolerated and safe for the low-dose and medium dose cohorts. Secondary endpoints showed promising improvements.
Authors
- Christopher Duma (ORCID: https://orcid.org/0000-0003-3943-2030)
- Hans S. Keirstead (ORCID: https://orcid.org/0000-0002-7086-4408)
- Karlyssa Chung
- Sawyer H. Farmer (ORCID: https://orcid.org/0009-0006-4160-9535)
- Robert Lynn
- Ashley Harris
- Gustavo Alva
- Jessica J. Buxton
- Zoe Hareng
- Gabriel Nistor
Institutions
- California Institute for Regenerative Medicine (US)
- ATP Clinical Research (United States) (US)
- Albany Medical Center Hospital (US)
- University of California, Berkeley (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108493
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00